102 related articles for article (PubMed ID: 23064061)
1. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
[TBL] [Abstract][Full Text] [Related]
2. [Study of use of pemetrexed in non-small cell lung cancer].
Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
[TBL] [Abstract][Full Text] [Related]
3. Pemetrexed and maintenance therapy for non-small cell lung cancer.
Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
[No Abstract] [Full Text] [Related]
4. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
[TBL] [Abstract][Full Text] [Related]
5. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
[TBL] [Abstract][Full Text] [Related]
6. [Update of pemetrexed in thoracic oncology].
Brechot JM; Morère JF
Bull Cancer; 2007; 94 Spec No Actualites():S139-41. PubMed ID: 17845984
[TBL] [Abstract][Full Text] [Related]
7. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
[TBL] [Abstract][Full Text] [Related]
8. [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed].
Tsuda Y; Kitamura A; Nishimura N; Yagi N; Takayama S; Okafuji K; Tomishima Y; Jinta T; Koyama K; Ohde S; Gotoh K; Chohnabayashi N
Gan To Kagaku Ryoho; 2015 Apr; 42(4):471-5. PubMed ID: 25963695
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
Zhang YF; Chen ZW; Lu S
Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
[TBL] [Abstract][Full Text] [Related]
10. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of Pemetrexed Monotherapy in Advanced Non-Small Cell Lung Cancer Patients with Impaired Renal Function].
Funaguchi N; Nakajima Y; Kaito D; Yanase K; Ito F; Endo J; Morishita M; Asano M; Iihara H; Mori H; Ohno Y; Minatoguchi S
Gan To Kagaku Ryoho; 2015 Jun; 42(6):705-8. PubMed ID: 26199241
[TBL] [Abstract][Full Text] [Related]
12. Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study.
Gridelli C; de Marinis F; Thomas M; Prabhash K; El Kouri C; Blackhall F; Bustin F; Pujol JL; John WJ; San Antonio B; Zimmermann A; Chouaki N; Visseren-Grul C; Paz-Ares LG
J Thorac Oncol; 2014 Jul; 9(7):991-997. PubMed ID: 24926544
[TBL] [Abstract][Full Text] [Related]
13. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
[No Abstract] [Full Text] [Related]
14. [The efficacy and safety of pemetrexed as monotherapy for Chinese patients with advanced non-small cell lung cancer].
Zhong W; Zhao J; Zhang XT; Zhang L; Wang MZ; Li LY
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):671-4. PubMed ID: 20979786
[TBL] [Abstract][Full Text] [Related]
15. [Second-line treatment of advanced non-small-cell lung cancer: role of pemetrexed].
Pérol M
Rev Pneumol Clin; 2005 Sep; 61(4 Pt 2):4S14-7. PubMed ID: 16273004
[No Abstract] [Full Text] [Related]
16. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
18. [Safety and effectiveness of pemetrexed in patients with non-small cell lung cancer in Japan - analysis of post-marketing surveillance].
Okubo S; Kobayashi N; Taketsuna M; Kaneko N; Enatsu S; Nishiuma S
Gan To Kagaku Ryoho; 2014 Apr; 41(4):475-81. PubMed ID: 24743364
[TBL] [Abstract][Full Text] [Related]
19. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
Bearz A; Garassino I; Cavina R; Favaretto A; Boccalon M; Talamini R; Berretta M; Spazzapan S; Simonelli C; Santoro A; Tirelli U
Lung Cancer; 2008 May; 60(2):240-5. PubMed ID: 18022729
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics.
Gridelli C; Rossi A; Morgillo F; Bareschino MA; Maione P; Di Maio M; Ciardiello F
Clin Lung Cancer; 2007 Nov; 8(9):568-71. PubMed ID: 18186963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
